Company profile

LEO Pharma

Privately held: no public share price

Assets

(3 total)
3Total Assets
2Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Calcipotriene/Betamethasone Dipropionate Foam(Enstilar)
Approved
Vitamin D receptor + Glucocorticoid receptorSmall molecule
Psoriasis
tralokinumab(Adbry)
Approved
IL-13 · Undisclosed / early pipelineMonoclonal antibody
Atopic Dermatitis
temtokibart
Phase 3
IL-22 receptor subunit alpha-1 (IL-22RA1)Monoclonal antibody
Atopic Dermatitis

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.